Acasti Pharma, Inc. (ACST)

Acasti Pharma (ACST) Income Statement


Acasti Pharma Income Statement

Last quarter (Q3 2023), Acasti Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Acasti Pharma's net income was $-3.89M. See Acasti Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 22Mar 21Mar 20Mar 19Mar 17
Total Revenue
--$ 196.00K$ 0.00$ 0.00$ 0.00
Cost of Revenue
--$ 76.00K$ 0.00--
Gross Profit
--$ 120.00K$ 0.00--
Operating Expense
$ 18.49M$ 15.34M$ 10.84M$ 24.44M$ 33.66M$ 8.41M
Operating Income
$ -18.49M$ -15.34M$ -10.72M$ -24.44M$ -33.66M$ -8.41M
Net Non Operating Interest Income Expense
$ 168.00K$ 77.00K$ -157.00K$ 43.00K$ -427.00K$ 50.24K
Other Income Expense
$ -262.00K$ -5.34M$ -8.80M$ -1.12M$ -5.27M$ -174.72K
Pretax Income
$ -18.57M$ -10.47M$ -19.68M$ -25.51M$ -39.37M$ -8.53M
Tax Provision
$ -671.00K$ -648.00K--$ 0.00$ -96.73K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -17.25M$ -9.82M$ -19.68M$ -25.51M$ -39.37M$ -8.43M
Basic EPS
$ -0.39$ -270.00$ -1.36$ -2.40$ -0.73$ -0.76
Diluted EPS
$ -0.39$ -270.00$ -1.36$ -2.40$ -0.73$ -0.76
Basic Average Shares
$ 177.78M$ 36.84B$ 14.83M$ 10.57M$ 54.29M$ 11.09M
Diluted Average Shares
$ 177.78M$ 36.84B$ 14.83M$ 10.57M$ 54.29M$ 11.09M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
-----$ 121.00K
Total Expenses
$ 14.24M-$ 10.91M$ 24.44M$ 33.66M$ 8.41M
Net Income From Continuing And Discontinued Operation
$ -17.25M$ -9.82M$ -19.68M$ -25.51M$ -39.37M$ -8.43M
Normalized Income
$ -17.54M$ -11.12M$ -10.87M$ -24.39M$ -34.09M$ -8.26M
Interest Expense
--$ 0.00$ 247.00K$ 278.00K$ 29.24K
$ -18.47M$ -10.54M$ -19.68M$ -25.27M$ -39.09M$ -8.50M
$ -14.09M-$ -18.75M$ -22.95M$ -36.76M$ -6.45M
Currency in USD

Acasti Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis